source
- UK regulator reports rise in drug approvals and steps to regulate AI in healthcareThe Medicines and Healthcare products Regulatory Agency (MHRA) presented its 2025-2026 annual report to Parliament, highlighting a higher number of new drug approvals compared with the previous yea…
- Tempus AI to acquire cancer test maker Personalis for $1.5 billionTempus AI announced it will buy Personalis, a Fremont-based company that offers a molecular residual disease test for cancer, in a deal valued at $1.5 billion. The acquisition is expected to expan…